Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, announced one of the largest layoffs in the company's history on September 10, 2025 — cutting approximately 9,000 positions, or roughly 11% of its global workforce of 78,400 employees.The sweeping restructuring, the first major decision by incoming CEO Mike Doustdar, targets annual savings of around $1.25 billion by the end of 2026, as the company battles slowing sales growth, rising competition from Eli Lilly, and mounting pressure from cheaper compounded versions of its blockbuster GLP-1 drugs.
How Many Jobs Did Novo Nordisk Cut?
Novo Nordisk confirmed it would eliminate approximately 9,000 positions globally , with roughly 5,000 of those cuts concentrated in Denmark , where the company is headquartered in Bagsværd. The remaining reductions affect operations across more than 160 countries where Novo Nordisk operates.
The layoffs represent the steepest headcount reduction in the company's recent history, coming on the heels of a period of rapid expansion — Novo Nordisk nearly doubled its workforce from 43,260 employees in 2019 to 77,350 by 2023, driven by surging demand for Ozempic and Wegovy.
Why Is Novo Nordisk Laying Off Workers?
Slowing GLP-1 Sales and Competitive Pressure
The core driver is a sharp deceleration in revenue growth for Novo Nordisk's flagship GLP-1 therapies. While Ozempic and Wegovy once dominated the weight loss and diabetes treatment market, Eli Lilly has steadily gained ground with Mounjaro and Zepbound. Clinical studies have suggested Lilly's tirzepatide may produce greater weight loss than semaglutide, contributing to a market share shift that Novo Nordisk has struggled to reverse.
Compounding the problem, compounded versions of semaglutide from telehealth platforms and specialty pharmacies continue to siphon customers, despite Novo Nordisk's more than 130 lawsuits against compounders and a formal FDA determination that the semaglutide shortage has ended.
Novo Nordisk's stock fell approximately 37% in the year leading up to the announcement, erasing hundreds of billions in market capitalization. In late July 2025 alone, shares dropped 21.7% after the company cut its sales outlook, wiping roughly $70 billion from its market value in a single session.
New CEO, New Direction
Mike Doustdar assumed the CEO position in August 2025, succeeding Lars Fruergaard Jørgensen, whose departure was announced in May amid the share price decline and mounting market challenges. Doustdar moved quickly, announcing the restructuring just over a month into his tenure.
"Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven," Doustdar said in a statement. "Our company must evolve as well."
In a LinkedIn post accompanying the announcement, Doustdar wrote: "Sometimes the hardest decisions are the right ones for the future we're building."
The restructuring is designed to simplify Novo Nordisk's organizational structure, reduce decision-making complexity added during its rapid growth phase, and redirect resources into diabetes and obesity research, commercial execution, and manufacturing scale-up.
Financial Impact of the Restructuring
The layoffs carry a significant one-time cost: Novo Nordisk expects to book approximately $1.41 billion in restructuring charges in Q3 2025 , with an additional $157 million in offsetting savings in Q4.
As a result, the company revised its 2025 full-year operating profit growth forecast down to 4%–10% at constant exchange rates, from a prior guidance range of 10%–16% — itself already a downward revision from an earlier target of 16%–24% set in May.
The annual savings from the restructuring, projected at approximately $1.25 billion by end of 2026, are intended to be reinvested into the company's core growth areas rather than returned purely as cost reduction.
Novo Nordisk Layoffs at Clayton, North Carolina
In October 2025, Reuters confirmed that the restructuring had reached Novo Nordisk's largest U.S. manufacturing facility in Clayton, North Carolina. The Clayton plant — the company's first site outside Denmark to produce active pharmaceutical ingredients — manufactures semaglutide, the active compound in Ozempic, Wegovy, and the oral therapy Rybelsus.
Affected roles at the Clayton facility and nearby sites included production line technicians, quality control specialists, project coordinators, a strategic communications manager, and HR staff. The exact number of U.S. cuts has not been formally disclosed.
Novo Nordisk has maintained a presence in Clayton since 1993 and completed a second, $2 billion plant there in 2021 — at the time the largest life sciences project in North Carolina history.
Return-to-Office Requirement
Alongside the job cuts, Novo Nordisk announced that all employees would be expected to return to the office full-time, ending work-from-home arrangements that had been in place since the pandemic. Doustdar linked the policy change to his goals of faster decision-making and stronger commercial execution.
The move drew criticism from Danish trade unions. HK Privat, a union representing Novo Nordisk administrative staff, expressed surprise at the timing and scope of the policy change, with chair Kim Jung Olsen noting that office culture and remote work flexibility are "not necessarily mutually exclusive." Novo Nordisk clarified that individual managers retain some flexibility to accommodate personal and business needs on a case-by-case basis.
Broader Pharma Layoff Context
Novo Nordisk's cuts are part of a wider wave of pharmaceutical industry job reductions in 2025. Bayer eliminated 12,000 positions under CEO Bill Anderson's restructuring push. Merck announced it would reduce headcount by 3,000 as part of a $3 billion cost-saving initiative. Moderna cut approximately 10% of its workforce, bringing global staff to under 5,000 employees.
The trend reflects a post-pandemic correction across the industry, as companies that rapidly expanded during the COVID era and GLP-1 boom now face slower growth, increased generic and biosimilar competition, and investor pressure to improve profitability.
What Happens Next
Novo Nordisk has said the restructuring will begin "immediately," with affected employees receiving layoff notifications over several months, subject to local labor laws and union negotiations — particularly in Denmark, where labor protections require extended consultation processes.
The company's priority going forward is sharpening its competitive position in obesity and diabetes, where it still holds significant advantages in brand recognition, scale, and pipeline depth. Analysts at UBS noted that the key question for investors is "when could the topline see the benefit of the reinvestment," and warned that skepticism would persist until a concrete growth plan is outlined.